Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPIDIRON: IV Iron vs Oral Iron for Anemia in Pregnancy
NCT05358509Phase 4Completed
- Sponsor
- Thomas Jefferson University
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose and ferric derisomaltose in iron deficiency anemia (IDA) (3 arms), sponsored by Thomas Jefferson University. Primary endpoints: Return to non-anemic status (Hb >= 11 g/dL) and Low birth weight (<2500 grams) deliveries. Started Mar 2021; status: completed.
02
Drugs
ferric carboxymaltoseferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05358509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358509.